Retatrutide - Top-Line Results from TRIUMPH 4
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Retatrutide - Top-Line Results from TRIUMPH 4
-
Narrated by:
-
By:
About this listen
In this quick update, I break down the newest Phase 3 data for retatrutide, Lilly’s investigational triple-agonist medication showing unprecedented results in obesity and knee osteoarthritis.
Highlights:
- Up to 28.7% weight loss (~71 lbs) over 68 weeks
- 75% reduction in knee pain and major improvements in physical function
- Cardiometabolic benefits: lower triglycerides, non-HDL cholesterol, hsCRP, and blood pressure
We also cover
- Common side effects and safety signals
- Perceived excessive weight loss — and what this means for clinical practice in a new era of powerful medications
- A reality check on Canadian availability (likely 3+ years away)
- A strong warning about illegal online sales and the risks of buying unregulated products
A concise medical breakdown to help you stay informed and safe as the obesity-medicine landscape evolves.
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.